One To Watch
Bio-Thera Solutions
Headquarters and Global Presence
Bio-Thera is headquartered in Guangzhou and supplies products in China and international markets. Ex-China access is primarily delivered through licensing and commercialization partners (typically the local marketing authorization holder), with Bio-Thera responsible for development, manufacturing and supply.
Founding and History
Bio-Thera is listed on the STAR Market of the Shanghai Stock Exchange (688177.SH). The company has built scale around biosimilars and antibody engineering, while advancing an oncology innovation pipeline that includes antibody-drug conjugates.
Therapy Areas and Focus
Bio-Thera’s disclosed R&D focus spans:
- Autoimmune and inflammatory diseases, largely via biosimilars and lifecycle expansion
- Oncology, including antibody-drug conjugates and immuno-oncology programs
- Cardiovascular diseases (selected programs)
- Ophthalmology (selected programs)
Technology Platforms and Modalities
Bio-Thera’s portfolio is centered on biologics, including:
- Biosimilar monoclonal antibodies, supported by analytical comparability and clinical confirmation packages
- Antibody engineering and next-generation antibody discovery
- Antibody-drug conjugates for solid tumors, including target selection and payload-linker development
- Immuno-oncology assets positioned for combination use in post–PD-1 treatment settings
Products and Clinical Pipeline
Approved and marketed products (selected)
- QLETLI (adalimumab) in China
- BETAGRIN (bevifibatide citrate) injection in China
- TOFIDENCE (tocilizumab biosimilar; BAT1806) in the US and EU
- AVZIVI (bevacizumab biosimilar) in the US and EU; marketed as POBEVCY in China
- Ustekinumab biosimilar approvals in major markets via partners (US and EU commercial brands disclosed by partners)
Late-stage and notable development programs (selected)
- BAT8006, a folate receptor alpha–targeting ADC: Phase III in platinum-resistant ovarian cancer
- BAT2506, a golimumab biosimilar referencing Simponi: regulatory review and Europe-facing commercialization planning via partner channels
- Additional biosimilar candidates disclosed by the company, including a secukinumab biosimilar candidate (Cosentyx reference) under regional licensing arrangements
Strategic Partnerships
Bio-Thera uses regional partners to execute filings, commercialization and market access outside China while retaining development/manufacturing responsibility. Publicly disclosed partner relationships include:
- STADA for golimumab (BAT2506; intended EU/UK/Swiss commercialization) and broader alliance expansion
- Gedeon Richter for ustekinumab biosimilar commercialization in Europe
- Hikma for ustekinumab biosimilar commercialization in the US
- Accord BioPharma for US regulatory filing and potential commercialization of BAT2506 (golimumab)
- Dr. Reddy’s for biosimilar commercialization rights in parts of Southeast Asia (expanded to additional biosimilar candidates)
- Avalon Pharma for regional commercialization arrangements in Saudi Arabia/MENA for selected assets (as disclosed in Bio-Thera’s company news)
FAQ Section
Bio-Thera combines a marketed biologics portfolio (primarily biosimilars) with an innovation pipeline in oncology. The operating model is built around internal biologics R&D and manufacturing, with partner-led regulatory filing and commercialization outside China.
The company’s activity spans oncology and immunology/inflammation as primary areas, with additional programs in cardiovascular disease and ophthalmology. In practice, biosimilars drive much of the near-term commercial footprint, while oncology innovation (including ADCs) represents the main proprietary pipeline theme.
Bio-Thera has disclosed five approved products across China, the US and the EU, including adalimumab and bevifibatide in China and multiple biosimilars internationally (tocilizumab and bevacizumab among the best established), alongside ustekinumab biosimilar approvals via partners.
Most recent items, in reverse chronological order:
- December 2025: STADA and Bio-Thera reported a positive CHMP opinion recommending approval of their golimumab biosimilar (Gotenfia; BAT2506) in Europe.
- November 2025: Bio-Thera expanded its partnership with Dr. Reddy’s for an exclusive commercialization and license agreement covering BAT2306, a proposed secukinumab biosimilar candidate, in Southeast Asia.
- August 2025: European Commission approval announced for BAT2206 (ustekinumab biosimilar) for EU commercialization via partner channels.
- July 2025: The FDA accepted the BLA for BAT2506 (golimumab biosimilar) with a BsUFA goal date of May 16, 2026 (US filing via partner structure).
- June 2025: First patient dosed in the Phase III trial of BAT8006 (FRα-targeting ADC) in platinum-resistant ovarian cancer.
BAT8006 is an antibody-drug conjugate targeting folate receptor alpha, being developed for ovarian cancer. It is positioned as one of Bio-Thera’s most advanced proprietary oncology programs, with a Phase III study underway in platinum-resistant disease.
Key execution milestones include:
- Regulatory progress for BAT2506 (golimumab biosimilar) in the US (FDA review) and Europe (European Commission decision following CHMP opinion)
- Enrollment progress and eventual readout timing for BAT8006 Phase III
- Additional partner-led launches and territory expansions for approved biosimilars
Bio-Thera commonly develops and manufactures the biologic, while a regional partner files for local approval, holds the marketing authorization and commercializes. This approach is used to scale access across geographies while keeping Bio-Thera’s internal focus on R&D, manufacturing and supply reliability.
Latest Bio-Thera Solutions News
Today's issue
| Headless Content Management with Blaze